Search Results | Blood | American Society of Hematology

1-20 of 214

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Blood (2022) 139 (23): 3376–3386.

DOI: https://doi.org/10.1182/blood.2021013733

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax Plus Hypomethylating Agent for the Salvage Treatment of Myeloid Malignancies Relapsing after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation

Fei Gao, Yi Luo, Jian Yu, Huarui Fu, Xiaoyu Lai, Lizhen Liu, Baodong Ye, Jianping Lan, Xiaolu Song, Ying Lu, Lieguang Chen, Yi Chen, Kang Yu, He Huang, Jimin Shi, Yanmin Zhao

Blood (2021) 138 (Supplement 1): 1825.

DOI: https://doi.org/10.1182/blood-2021-146364

Published: 2021

Journal Articles

Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy

Yue Huang, Houli Zhao, Mi Shao, Linghui Zhou, Guoqing Wei, Wenjun Wu, Alex Hong Chang, Tao Sun, Yongxian HU, He Huang

Blood (2021) 138 (Supplement 1): 2842.

DOI: https://doi.org/10.1182/blood-2021-149928

Published: 2021

Journal Articles

Comparison of Prophylactic and Preemptive Donor Lymphocyte Infusion in Patients with Very High Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Luxin Yang, Yi Luo, He Huang, Yamin Tan, Jimin Shi, Yanmin Zhao, Jian Yu, Xiaoyu Lai

Blood (2021) 138 (Supplement 1): 3860.

DOI: https://doi.org/10.1182/blood-2021-152578

Published: 2021

Journal Articles

Invasive Field Radiotherapy Combined with Rituximab Versus Rituximab Alone for Consolidation Therapy in Stage III Follicular Lymphoma Patients Response to R-CHOP Chemotherapy: A Randomized Clinical Study

Blood (2021) 138 (Supplement 1): 3531.

DOI: https://doi.org/10.1182/blood-2021-146338

Published: 2021

Journal Articles

Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Xiaoxiao Wang, Yan Gao, Shanshan Yu, Bing Bai, Qiuxiang Ou, Liuqing Zhu, He Huang, Hui Zhou, Yang Shao, Linbo Cai, Hui-qiang Huang

Blood (2021) 138 (Supplement 1): 2481.

DOI: https://doi.org/10.1182/blood-2021-150658

Published: 2021

Journal Articles

ALKBH5 Functions As an Oncogene in Multiple Myeloma

Jianwei Qu, Yifan Hou, Qingxiao Chen, Jing Chen, YI LI, Enfan Zhang, Huiyao Gu, Ruyi Xu, Yang Liu, Jingsong He, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 3326.

DOI: https://doi.org/10.1182/blood-2021-149622

Published: 2021

Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 547.

DOI: https://doi.org/10.1182/blood-2021-152576

Published: 2021

Journal Articles

Central Nervous System Involvement in Extranodal Natural Killer/T-Cell Lymphoma: Case Series

Qingqing Cai, Jinni Wang, Yu Fang, Ning Su, Shuyun Ma, Jun Cai, Yuchen Zhang, Xiaopeng Tian, Huiqiang Huang, Zhiming Li, He Huang, Yi Xia, Panpan Liu

Blood (2021) 138 (Supplement 1): 1399.

DOI: https://doi.org/10.1182/blood-2021-150205

Published: 2021

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

DOI: https://doi.org/10.1182/blood-2021-149188

Published: 2021

Journal Articles

Effect of Donor Characteristics on T Cell Replete Haploidentical Stem Cell Transplantation: Over the Last 10 Years at a Single Institution

Yi Luo, Yibo Wu, Jimin Shi, Yamin Tan, Jian Yu, Yanmin Zhao, Xiaoyu Lai, Lizhen Liu, He Huang

Blood (2021) 138 (Supplement 1): 3927.

DOI: https://doi.org/10.1182/blood-2021-152641

Published: 2021

Journal Articles

Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation

Hengwei Wu, Ji Min Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Guifang Ouyang, Xiaojun Xu, Xiao Haowen, He Huang, Yanmin Zhao

Blood (2021) 138 (Supplement 1): 3930.

DOI: https://doi.org/10.1182/blood-2021-147153

Published: 2021

Journal Articles

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy

Ruimin Hong, Houli Zhao, MD, Yiyun Wang, Yu Chen, Hongliu Cai, Yongxian Hu, MD, Guoqing Wei, MD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

DOI: https://doi.org/10.1182/blood-2020-139007

Published: 2020

Journal Articles

Salvage Therapy with Low-Dose Ruxolitinib Led to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients with cGvHD after Allogeneic Hematopoietic Stem Cell Transplantation

He Huang, MD PhD, Yanmin Zhao, MD, Guifang Ouyang, Jimin Shi, MD, Yi Luo, MD, Yamin Tan, MD, Jian Yu, MD, Huarui Fu, MD, Xiaoyu Lai, MD, Lizhen Liu, MD

Blood (2020) 136 (Supplement 1): 43–44.

DOI: https://doi.org/10.1182/blood-2020-141546

Published: 2020

Journal Articles

Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

Hengwei Wu, MD, Jimin Shi, MD, Yi Luo, MD, Yamin Tan, MD, Mingming Zhang, MD, Xiaoyu Lai, MD, Jian Yu, MD, Lizhen Liu, MD, Huarui Fu, MD, He Huang, MD PhD, Yanmin Zhao, MD

Blood (2020) 136 (Supplement 1): 1.

DOI: https://doi.org/10.1182/blood-2020-141561

Published: 2020

Journal Articles

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, MD, Yali Zhou, Mingming Zhang, MD, Wengang Ge, Yi Li, MD, Li Yang, MD, Guoqing Wei, MD, Lu Han, Hao Wang, Xingwang Zhang, PhD, Jiangtao Ren, PhD, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 52.

DOI: https://doi.org/10.1182/blood-2020-142262

Published: 2020

Journal Articles

CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study

Yongxian Hu, MD, Yanlei Zhang, Houli Zhao, MD, Yiyun Wang, Arnon Nagler, MD, Alex Hong Chang, He Huang, MD PhD

Blood (2020) 136 (Supplement 1): 34.

DOI: https://doi.org/10.1182/blood-2020-143239

Published: 2020

Journal Articles

Eltrombopag Treatment for Patients with Thrombocytopenia Post-Transplantation Showed a Good Chance of Platelet Recovery

Fei Gao, MD, Yanmin Zhao, MD, He Huang, MD PhD

Blood (2019) 134 (Supplement_1): 5658.

DOI: https://doi.org/10.1182/blood-2019-125759

Published: 2019

Journal Articles

Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

Yongxian Hu, MD, Zhang Yanlei, Guoqing Wei, Chang alex Hong, He Huang

Blood (2019) 134 (Supplement_1): 1859.

DOI: https://doi.org/10.1182/blood-2019-130341

Published: 2019

Journal Articles

TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8

Hengyou Weng, PhD, Huilin Huang, PhD, He Huang, Zhaojin Yu, Paulina Siejka-Zielinska, Zhenhua Chen, PhD, Emily Prince, Chao Shen, PhD, Zejuan Li, MD, Chunxiao Song, Yingming Zhao, Jianjun Chen, PhD

Blood (2019) 134 (Supplement_1): 1249.

DOI: https://doi.org/10.1182/blood-2019-127321

Published: 2019

2 3 4 5

NARROW

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Venetoclax Plus Hypomethylating Agent for the Salvage Treatment of Myeloid Malignancies Relapsing after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation

Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy

Comparison of Prophylactic and Preemptive Donor Lymphocyte Infusion in Patients with Very High Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Invasive Field Radiotherapy Combined with Rituximab Versus Rituximab Alone for Consolidation Therapy in Stage III Follicular Lymphoma Patients Response to R-CHOP Chemotherapy: A Randomized Clinical Study

Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

ALKBH5 Functions As an Oncogene in Multiple Myeloma

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Central Nervous System Involvement in Extranodal Natural Killer/T-Cell Lymphoma: Case Series

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Effect of Donor Characteristics on T Cell Replete Haploidentical Stem Cell Transplantation: Over the Last 10 Years at a Single Institution

Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy

Salvage Therapy with Low-Dose Ruxolitinib Led to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients with cGvHD after Allogeneic Hematopoietic Stem Cell Transplantation

Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study

Eltrombopag Treatment for Patients with Thrombocytopenia Post-Transplantation Showed a Good Chance of Platelet Recovery

Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only